Cập nhật về nhóm thuốc ức chế kênh đồng vận chuyển SGLT-2 trong điều trị đái tháo đường

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Thị Thu Ngân Đinh

Ngôn ngữ: vie

Ký hiệu phân loại: 641.56314 Cooking

Thông tin xuất bản: Khoa học và Công nghệ (Đại học Thái Nguyên), 2018

Mô tả vật lý: 45358

Bộ sưu tập: Metadata

ID: 491139

Thêm vào giỏ

Tóm tắt
Chủ đề

Nhóm thuốc ức chế SGLT-2 là nhóm thuốc mới, tuy nhiên tỏ ra có hiệu quả và dung nạp tốt khu sử dụng đơn trị và kể cả khi dùng kết hợp với thuốc hạ glucose máu khác ở bệnh nhân đái tháo đường typ 2. Nhóm thuốc này có một tương lai đầy hứa hẹn. Tuy nhiên, cần thêm thời gian để đánh giá một cách chính xác về hiệu quả và độ an toàn.SGLT - 2 inhibitors are new drugs that have been recently approved by FDA ((U.S. Food & Drug Administration) for treating type 2 diabetes. In clinical trials, these drugs have demonstrated their effects in lowering blood glucose level as well as HbA1c. In addition, they also have reduced weight, systolic blood pressure and blood uric acid. Nevertheless, there have been some common adverse effects of these drugs, like genital mycotic infection, urinary tract infection, osmotic diuresis and volume depletion. Recently, FDA and EMA (European Medicines agency) have showed some warnings associating with common adverse effects of these drugs. SGLT - 2 inhibitors have been proven that they not only can be used in type 2 diabetes, but also have potential in combining with insulin in type 1 diabetes. However, researchers need more time to evaluate exactly about effects and safety of these drugs

Tạo bộ sưu tập với mã QR